Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Pennsylvania Kos Pharmaceuticals |
---|---|
Information provided by: | University of Pennsylvania |
ClinicalTrials.gov Identifier: | NCT00300365 |
Condition | Intervention | Phase |
---|---|---|
Metabolic Syndrome |
Drug: Pioglitazone +/- placebo in combination with niacin ER |
Phase IV |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double Blind, Placebo Controlled Trial of Pioglitazone and Niacin Extended Release in Non-Diabetic Patients With Metabolic Syndrome |
Estimated Enrollment: | 84 |
Study Start Date: | November 2005 |
This is a two-arm, parallel, double-blind randomized prospective clinical trial. The subjects will be asked to provide informed consent, and then undergo screening for enrollment criteria at the first visit (-5 weeks). The subjects who are eligible, and provide informed consent will return for Visit 2 baseline data (-4 weeks), and then begin the unblinded niacin-ER titration. Specifically, subjects will receive a starting dose of niacin-ER of 500 mg per day, which will be increased in 500 mg increments every week up to a dose of 2000 mg per day. Subjects will need to tolerate at least 1500 mg per day of niacin-ER in order to remain in the study and be randomized. Thus subjects who are unable to tolerate the 2000 mg daily dose of niacin-ER will be taken back to 1500 mg per day for one week and then randomized. Subjects who develop prohibitive side effects at doses less than 1500 mg per day will be discontinued from the study. All subjects who are able to take the target dose of niacin-ER will continue that dose of niacin-ER and come to the GCRC to be randomized in a 1:1 fashion to either niacin-ER plus pioglitazone or niacin-ER plus matching placebo for 12 weeks. Pioglitazone will be started at 30 mg and then increased to 45 mg at week 6. This entry design is designed to minimize the differences in mean dose of niacin-ER and dropout rate between study groups.
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
At least two of the following criteria (a, b, c, or d) listed below:
Exclusion Criteria:
Contact: Rick Samaha, MD | (215) 823-6324 | rick.samaha@med.va.gov |
United States, Pennsylvania | |
University of Pennsylvania | Recruiting |
Philadelphia, Pennsylvania, United States, 19104 | |
Contact: Rick Samaha, MD 215-823-6324 rick.samaha@med.va.gov |
Principal Investigator: | Rick Samaha, MD | University of Pennsylvania |
Study ID Numbers: | 803751, Pionir |
Study First Received: | March 6, 2006 |
Last Updated: | May 19, 2006 |
ClinicalTrials.gov Identifier: | NCT00300365 |
Health Authority: | United States: Food and Drug Administration |
HDL cholesterol Metabolic syndrome |
Nicotinic Acids Pioglitazone Niacin |
Antimetabolites Vasodilator Agents Disease Vitamin B Complex Molecular Mechanisms of Pharmacological Action Growth Substances Antilipemic Agents Physiological Effects of Drugs |
Cardiovascular Agents Pharmacologic Actions Hypoglycemic Agents Pathologic Processes Syndrome Therapeutic Uses Vitamins Micronutrients |